PMID- 31140557
OWN - NLM
STAT- MEDLINE
DCOM- 20201110
LR  - 20220812
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Print)
IS  - 1522-8517 (Linking)
VI  - 21
IP  - 9
DP  - 2019 Sep 6
TI  - Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial 
      tumors.
PG  - 1164-1174
LID - 10.1093/neuonc/noz098 [doi]
AB  - BACKGROUND: Chromosomal instability is associated with earlier progression in 
      isocitrate dehydrogenase (IDH)-mutated astrocytomas. Here we evaluated the 
      prognostic significance of polysomy in gliomas tested for 1p/19q status. METHODS: 
      We analyzed 412 histologic oligodendroglial tumors with use of 1p/19q testing at 
      8 institutions from 1996 to 2013; fluorescence in situ hybridization (FISH) for 
      1p/19q was performed. Polysomy was defined as more than two 1q and 19p signals in 
      cells. Tumors were divided into groups on the basis of their 1p/19q status and 
      polysomy and were compared for progression-free survival (PFS) and overall 
      survival (OS). RESULTS: In our cohort, 333 tumors (81%) had 1p/19q loss; of 
      these, 195 (59%) had concurrent polysomy and 138 (41%) lacked polysomy, 79 (19%) 
      had 1p/19q maintenance; of these, 30 (38%) had concurrent polysomy and 49 (62%) 
      lacked polysomy. In agreement with prior studies, the group with 1p/19q loss had 
      significantly better PFS and OS than did the group with 1p/19q maintenance (P < 
      0.0001 each). Patients with 1p/19q loss and polysomy showed significantly shorter 
      PFS survival than patients with 1p/19q codeletion only (P < 0.0001), but longer 
      PFS and OS than patients with 1p/19q maintenance (P < 0.01 and P < 0.0001). There 
      was no difference in survival between tumors with >30% polysomic cells and those 
      with <30% polysomic cells. Polysomy had no prognostic significance on PFS or OS 
      in patients with 1p/19q maintenance. CONCLUSIONS: The presence of polysomy in 
      oligodendroglial tumors with codeletion of 1p/19q predicts early recurrence and 
      short survival in patients with 1p/19q codeleted tumors.
CI  - (c) The Author(s) 2019. Published by Oxford University Press on behalf of the 
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Chen, Hui
AU  - Chen H
AD  - Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New 
      York.
FAU - Thomas, Cheddhi
AU  - Thomas C
AD  - Department of Pathology, NYU Langone Health, New York, New York.
FAU - Munoz, Felipe Andres
AU  - Munoz FA
AD  - Department of Biostatistics and Epidemiology, Rutgers University, School of 
      Public Health, Piscataway Township, New Jersey.
FAU - Alexandrescu, Sanda
AU  - Alexandrescu S
AD  - Department of Pathology, University of California San Francisco, San Francisco, 
      California.
FAU - Horbinski, Craig M
AU  - Horbinski CM
AD  - Department of Pathology, Northwestern University Feinberg School of Medicine, 
      Chicago, Illinois.
FAU - Olar, Adriana
AU  - Olar A
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - McGuone, Declan
AU  - McGuone D
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Camelo-Piragua, Sandra
AU  - Camelo-Piragua S
AD  - Department of Pathology, University of Michigan School of Medicine, Ann Arbor, 
      Michigan.
FAU - Wang, Lu
AU  - Wang L
AD  - Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New 
      York.
FAU - Pentsova, Elena
AU  - Pentsova E
AD  - Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New 
      York.
FAU - Phillips, Joanna
AU  - Phillips J
AD  - Department of Neurological Surgery, University of California San Francisco, San 
      Francisco, California.
FAU - Aldape, Kenneth
AU  - Aldape K
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Chen, Wen
AU  - Chen W
AD  - Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New 
      York.
FAU - Iafrate, A John
AU  - Iafrate AJ
AD  - Pathology Service, Massachusetts General Hospital, Boston, Massachusetts.
FAU - Chi, Andrew S
AU  - Chi AS
AD  - Neuro-Oncology Program, Perlmutter Cancer Center, NYU Langone Health, New York, 
      New York.
FAU - Zagzag, David
AU  - Zagzag D
AD  - Department of Neurosurgery, Perlmutter Cancer Center, NYU Langone Health, New 
      York, New York.
FAU - Golfinos, John G
AU  - Golfinos JG
AD  - Department of Neurosurgery, Perlmutter Cancer Center, NYU Langone Health, New 
      York, New York.
FAU - Placantonakis, Dimitris G
AU  - Placantonakis DG
AD  - Department of Neurosurgery, Perlmutter Cancer Center, NYU Langone Health, New 
      York, New York.
AD  - Kimmel Center for Stem Cell Biology, Neuroscience Institute, NYU Langone Health, 
      New York, New York.
FAU - Rosenblum, Marc
AU  - Rosenblum M
AD  - Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New 
      York.
FAU - Ohman-Strickland, Pamela
AU  - Ohman-Strickland P
AD  - Department of Biostatistics and Epidemiology, Rutgers University, School of 
      Public Health, Piscataway Township, New Jersey.
FAU - Hameed, Meera
AU  - Hameed M
AD  - Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New 
      York.
FAU - Snuderl, Matija
AU  - Snuderl M
AD  - Department of Pathology, NYU Langone Health, New York, New York.
LA  - eng
GR  - R01 NS102669/NS/NINDS NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R01 NS102665/NS/NINDS NIH HHS/United States
GR  - R03 NS087349/NS/NINDS NIH HHS/United States
GR  - P50 CA221747/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - EC 1.1.1.41 (IDH2 protein, human)
RN  - EC 1.1.1.41 (Isocitrate Dehydrogenase)
RN  - EC 1.1.1.42. (IDH1 protein, human)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Aneuploidy
MH  - Brain Neoplasms/*genetics/therapy
MH  - Chemotherapy, Adjuvant
MH  - Child
MH  - Chromosomal Instability
MH  - Chromosome Deletion
MH  - Chromosomes, Human, Pair 1/*genetics
MH  - Chromosomes, Human, Pair 19/*genetics
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Isocitrate Dehydrogenase/genetics
MH  - Male
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Neurosurgical Procedures
MH  - Oligodendroglioma/*genetics/therapy
MH  - Prognosis
MH  - Progression-Free Survival
MH  - Radiotherapy, Adjuvant
MH  - Survival Rate
MH  - Young Adult
PMC - PMC7571489
OTO - NOTNLM
OT  - 1p/19q codeletion
OT  - glioma
OT  - oligodendroglioma
OT  - polysomy
EDAT- 2019/05/30 06:00
MHDA- 2020/11/11 06:00
PMCR- 2020/05/29
CRDT- 2019/05/30 06:00
PHST- 2019/05/30 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2019/05/30 06:00 [entrez]
PHST- 2020/05/29 00:00 [pmc-release]
AID - 5505367 [pii]
AID - noz098 [pii]
AID - 10.1093/neuonc/noz098 [doi]
PST - ppublish
SO  - Neuro Oncol. 2019 Sep 6;21(9):1164-1174. doi: 10.1093/neuonc/noz098.